March 20 (Reuters) - The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain ...

Amneal to hold CREXONT launch symposium and scientific presentations at the International Congress of Parkinson’s Disease and Movement Disorders on Sept. 27 – Oct. 1, 2024 BRIDGEWATER, N.J.--(BUSINESS ...

New carbidopa/levodopa labels will state that seizures linked to vitamin B6 deficiency can ...

Treatment with Crexont statistically significantly improved “On” time without troublesome dyskinesia compared with carbidopa/levodopa IR. The Food and Drug Administration (FDA) has approved Crexont ® ...

CREXONT added to 3 large national formularies: Veterans Administration, UnitedHealthcare and CVS Health Increases insurance coverage to over 50% of covered lives CREXONT was approved by the U.S. FDA ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced drug delivery systems, today announced the ...

The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is a ...

In the late 1960s, scientists discovered a miracle drug for Parkinson’s disease — a simple, inexpensive dopamine-replacement pill called levodopa. It transformed the lives of millions of people.

Researchers in Australia have created a biodegradable gel that delivers Parkinson’s medications through a single weekly shot, replacing the need for multiple daily pills. Injected just under the skin, ...

A once-a-week Parkinson’s injection could replace multiple daily pills, thanks to a new slow-release formulation developed by researchers. It promises easier treatment, fewer missed doses, and better ...

Very long acting (> 6–8 h) levodopa preparations are still likely to represent the next chapter in the medical treatment of PD. Continuous-infusion levodopa gel, long-acting levodopa pills, ...

Researchers engineered a two-strain microbial system that converts PET-derived terephthalic acid into levodopa, overcoming key bottlenecks in transport and enzyme inhibition. The proof-of-concept ...